Cargando…

Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count

BACKGROUND: Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate immunogenicity according to current CD4 T-cell count METHODS: PLWH on ART attending a SARS-CoV-2 vaccination program, were included in a prospective immunogenicity evaluation afte...

Descripción completa

Detalles Bibliográficos
Autores principales: Antinori, Andrea, Cicalini, Stefania, Meschi, Silvia, Bordoni, Veronica, Lorenzini, Patrizia, Vergori, Alessandra, Lanini, Simone, De Pascale, Lidya, Matusali, Giulia, Mariotti, Davide, Cozzi Lepri, Alessandro, Gallì, Paola, Pinnetti, Carmela, Gagliardini, Roberta, Mazzotta, Valentina, Mastrorosa, Ilaria, Grisetti, Susanna, Colavita, Francesca, Cimini, Eleonora, Grilli, Elisabetta, Bellagamba, Rita, Lapa, Daniele, Sacchi, Alessandra, Marani, Alessandra, Cerini, Carlo, Candela, Caterina, Fusto, Marisa, Puro, Vincenzo, Castilletti, Concetta, Agrati, Chiara, Girardi, Enrico, Vaia, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047161/
https://www.ncbi.nlm.nih.gov/pubmed/35366316
http://dx.doi.org/10.1093/cid/ciac238
_version_ 1784695672343101440
author Antinori, Andrea
Cicalini, Stefania
Meschi, Silvia
Bordoni, Veronica
Lorenzini, Patrizia
Vergori, Alessandra
Lanini, Simone
De Pascale, Lidya
Matusali, Giulia
Mariotti, Davide
Cozzi Lepri, Alessandro
Gallì, Paola
Pinnetti, Carmela
Gagliardini, Roberta
Mazzotta, Valentina
Mastrorosa, Ilaria
Grisetti, Susanna
Colavita, Francesca
Cimini, Eleonora
Grilli, Elisabetta
Bellagamba, Rita
Lapa, Daniele
Sacchi, Alessandra
Marani, Alessandra
Cerini, Carlo
Candela, Caterina
Fusto, Marisa
Puro, Vincenzo
Castilletti, Concetta
Agrati, Chiara
Girardi, Enrico
Vaia, Francesco
author_facet Antinori, Andrea
Cicalini, Stefania
Meschi, Silvia
Bordoni, Veronica
Lorenzini, Patrizia
Vergori, Alessandra
Lanini, Simone
De Pascale, Lidya
Matusali, Giulia
Mariotti, Davide
Cozzi Lepri, Alessandro
Gallì, Paola
Pinnetti, Carmela
Gagliardini, Roberta
Mazzotta, Valentina
Mastrorosa, Ilaria
Grisetti, Susanna
Colavita, Francesca
Cimini, Eleonora
Grilli, Elisabetta
Bellagamba, Rita
Lapa, Daniele
Sacchi, Alessandra
Marani, Alessandra
Cerini, Carlo
Candela, Caterina
Fusto, Marisa
Puro, Vincenzo
Castilletti, Concetta
Agrati, Chiara
Girardi, Enrico
Vaia, Francesco
author_sort Antinori, Andrea
collection PubMed
description BACKGROUND: Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate immunogenicity according to current CD4 T-cell count METHODS: PLWH on ART attending a SARS-CoV-2 vaccination program, were included in a prospective immunogenicity evaluation after receiving BNT162b2 or mRNA-1273. Participants were stratified by current CD4 T-cell count (poor CD4 recovery, PCDR: <200/mm(3); intermediate CD4 recovery, ICDR: 200–500/mm(3); high CD4 recovery, HCDR: >500/mm(3)). RBD-binding IgG, SARS-CoV-2 neutralizing antibodies (nAbs) and IFN-γ release were measured. As control group, HIV-negative healthcare workers (HCWs) were used FINDINGS: Among 166 PLWH, after 1 month from the booster dose, detectable RBD-binding IgG were elicited in 86.7% of PCDR, 100% of ICDR, 98.7% of HCDR, and a neutralizing titre ≥1:10 elicited in 70.0%, 88.2%, and 93.1%, respectively. Compared to HCDR, all immune response parameters were significantly lower in PCDR. After adjusting for confounders, current CD4 T-cell <200/mm3 significantly predicted a poor magnitude of anti-RDB, nAbs and IFN-γ response. As compared with HCWs, PCDR elicited a consistently reduced immunogenicity for all parameters, ICDR only a reduced RBD-binding antibody response, whereas HCDR elicited a comparable immune response for all parameters CONCLUSION: Humoral and cell-mediated immune response against SARS-CoV-2 were elicited in most of PLWH, albeit significantly poorer in those with CD4 T-cell <200/mm(3) versus those with >500 cell/mm(3) and HIV-negative controls. A lower RBD-binding antibody response than HCWs was also observed in PLWH with CD4 T-cell 200–500/mm(3), whereas immune response elicited in PLWH with a CD4 T-cell >500/mm(3) was comparable to HIV-negative population
format Online
Article
Text
id pubmed-9047161
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-90471612022-04-28 Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count Antinori, Andrea Cicalini, Stefania Meschi, Silvia Bordoni, Veronica Lorenzini, Patrizia Vergori, Alessandra Lanini, Simone De Pascale, Lidya Matusali, Giulia Mariotti, Davide Cozzi Lepri, Alessandro Gallì, Paola Pinnetti, Carmela Gagliardini, Roberta Mazzotta, Valentina Mastrorosa, Ilaria Grisetti, Susanna Colavita, Francesca Cimini, Eleonora Grilli, Elisabetta Bellagamba, Rita Lapa, Daniele Sacchi, Alessandra Marani, Alessandra Cerini, Carlo Candela, Caterina Fusto, Marisa Puro, Vincenzo Castilletti, Concetta Agrati, Chiara Girardi, Enrico Vaia, Francesco Clin Infect Dis Major Article BACKGROUND: Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate immunogenicity according to current CD4 T-cell count METHODS: PLWH on ART attending a SARS-CoV-2 vaccination program, were included in a prospective immunogenicity evaluation after receiving BNT162b2 or mRNA-1273. Participants were stratified by current CD4 T-cell count (poor CD4 recovery, PCDR: <200/mm(3); intermediate CD4 recovery, ICDR: 200–500/mm(3); high CD4 recovery, HCDR: >500/mm(3)). RBD-binding IgG, SARS-CoV-2 neutralizing antibodies (nAbs) and IFN-γ release were measured. As control group, HIV-negative healthcare workers (HCWs) were used FINDINGS: Among 166 PLWH, after 1 month from the booster dose, detectable RBD-binding IgG were elicited in 86.7% of PCDR, 100% of ICDR, 98.7% of HCDR, and a neutralizing titre ≥1:10 elicited in 70.0%, 88.2%, and 93.1%, respectively. Compared to HCDR, all immune response parameters were significantly lower in PCDR. After adjusting for confounders, current CD4 T-cell <200/mm3 significantly predicted a poor magnitude of anti-RDB, nAbs and IFN-γ response. As compared with HCWs, PCDR elicited a consistently reduced immunogenicity for all parameters, ICDR only a reduced RBD-binding antibody response, whereas HCDR elicited a comparable immune response for all parameters CONCLUSION: Humoral and cell-mediated immune response against SARS-CoV-2 were elicited in most of PLWH, albeit significantly poorer in those with CD4 T-cell <200/mm(3) versus those with >500 cell/mm(3) and HIV-negative controls. A lower RBD-binding antibody response than HCWs was also observed in PLWH with CD4 T-cell 200–500/mm(3), whereas immune response elicited in PLWH with a CD4 T-cell >500/mm(3) was comparable to HIV-negative population Oxford University Press 2022-04-02 /pmc/articles/PMC9047161/ /pubmed/35366316 http://dx.doi.org/10.1093/cid/ciac238 Text en © The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Article
Antinori, Andrea
Cicalini, Stefania
Meschi, Silvia
Bordoni, Veronica
Lorenzini, Patrizia
Vergori, Alessandra
Lanini, Simone
De Pascale, Lidya
Matusali, Giulia
Mariotti, Davide
Cozzi Lepri, Alessandro
Gallì, Paola
Pinnetti, Carmela
Gagliardini, Roberta
Mazzotta, Valentina
Mastrorosa, Ilaria
Grisetti, Susanna
Colavita, Francesca
Cimini, Eleonora
Grilli, Elisabetta
Bellagamba, Rita
Lapa, Daniele
Sacchi, Alessandra
Marani, Alessandra
Cerini, Carlo
Candela, Caterina
Fusto, Marisa
Puro, Vincenzo
Castilletti, Concetta
Agrati, Chiara
Girardi, Enrico
Vaia, Francesco
Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count
title Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count
title_full Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count
title_fullStr Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count
title_full_unstemmed Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count
title_short Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count
title_sort humoral and cellular immune response elicited by mrna vaccination against severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in people living with human immunodeficiency virus receiving antiretroviral therapy based on current cd4 t-lymphocyte count
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047161/
https://www.ncbi.nlm.nih.gov/pubmed/35366316
http://dx.doi.org/10.1093/cid/ciac238
work_keys_str_mv AT antinoriandrea humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT cicalinistefania humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT meschisilvia humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT bordoniveronica humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT lorenzinipatrizia humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT vergorialessandra humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT laninisimone humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT depascalelidya humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT matusaligiulia humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT mariottidavide humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT cozzileprialessandro humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT gallipaola humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT pinnetticarmela humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT gagliardiniroberta humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT mazzottavalentina humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT mastrorosailaria humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT grisettisusanna humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT colavitafrancesca humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT ciminieleonora humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT grillielisabetta humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT bellagambarita humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT lapadaniele humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT sacchialessandra humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT maranialessandra humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT cerinicarlo humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT candelacaterina humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT fustomarisa humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT purovincenzo humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT castilletticoncetta humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT agratichiara humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT girardienrico humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT vaiafrancesco humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount
AT humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount